Karl Smith Byrne

Karl Smith Byrne was diagnosed with rectal cancer at 27, just months after completing his doctorate in cancer epidemiology. As a survivor and patient advocate, he brings the perspective of someone who has lived both sides of the research equation. He is committed to ensuring that research remains accountable to the people it aims to serve—championing patient and public involvement at every stage, from study design through to how findings are communicated. Karl works to make science accessible, transparent about uncertainty, and delivered to the communities who need it most.

As a researcher, Karl's work sits at the intersection of population health, molecular epidemiology, and cancer causes. He studies cancer risk and early disease processes, with a focus on developing new methods for therapeutic prevention. His research draws on large, well-characterized cohorts with detailed clinical follow-up, connecting biological mechanisms to real-world outcomes.

In the ATLAS team, Karl helps embed advocacy throughout the programme and works as part of the epidemiology team to ensure the Atlas remains open, scientifically rigorous, and centred on public and patient priorities. He is committed to interdisciplinary collaboration and research that translates into tangible benefit for patients and populations.